The ministerial commission asked the UK ACMD to specify which controlled cannabinoids should be controlled and set a unavoidable trace level for each of these within consumer CBD products.

1.1. Consumer Cannabidiol (CBD) products (i.e. CBD products which are not licensed medicines and which are available to purchase online or on the high street) are sold for their potential to produce ‘wellbeing’ benefits (Chesney, McGuire, Freeman, Strang, & Englund, 2020). CBD is a non-controlled cannabinoid present in Cannabis plant extracts. Currently the most commonly sold CBD product is CBD oil, however, the range of products containing CBD is expanding and includes food supplements, drinks, cosmetics and liquids for vaping. Consumer interest in CBD is growing (European Monitoring Centre for Drugs and Drug Addiction, 2019).....